Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.20
GRFS's Cash to Debt is ranked lower than
93% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. GRFS: 0.20 )
Ranked among companies with meaningful Cash to Debt only.
GRFS' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.24 Max: No Debt
Current: 0.2
Equity to Asset 0.35
GRFS's Equity to Asset is ranked lower than
80% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GRFS: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
GRFS' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.31 Max: 0.35
Current: 0.35
0.28
0.35
Interest Coverage 4.39
GRFS's Interest Coverage is ranked lower than
92% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 4.39 )
Ranked among companies with meaningful Interest Coverage only.
GRFS' s Interest Coverage Range Over the Past 10 Years
Min: 1.39  Med: 3.58 Max: 18.28
Current: 4.39
1.39
18.28
F-Score: 5
Z-Score: 1.99
M-Score: -4.05
WACC vs ROIC
6.63%
7.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.73
GRFS's Operating margin (%) is ranked higher than
89% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. GRFS: 25.73 )
Ranked among companies with meaningful Operating margin (%) only.
GRFS' s Operating margin (%) Range Over the Past 10 Years
Min: 15.53  Med: 25.00 Max: 26.85
Current: 25.73
15.53
26.85
Net-margin (%) 14.29
GRFS's Net-margin (%) is ranked higher than
83% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. GRFS: 14.29 )
Ranked among companies with meaningful Net-margin (%) only.
GRFS' s Net-margin (%) Range Over the Past 10 Years
Min: 2.8  Med: 12.13 Max: 16.2
Current: 14.29
2.8
16.2
ROE (%) 9.20
GRFS's ROE (%) is ranked higher than
85% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. GRFS: 9.20 )
Ranked among companies with meaningful ROE (%) only.
GRFS' s ROE (%) Range Over the Past 10 Years
Min: 4.27  Med: 17.37 Max: 19.76
Current: 9.2
4.27
19.76
ROA (%) 3.04
GRFS's ROA (%) is ranked higher than
82% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. GRFS: 3.04 )
Ranked among companies with meaningful ROA (%) only.
GRFS' s ROA (%) Range Over the Past 10 Years
Min: 1.31  Med: 6.03 Max: 6.58
Current: 3.04
1.31
6.58
ROC (Joel Greenblatt) (%) 18.66
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. GRFS: 18.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GRFS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 19.07  Med: 35.26 Max: 42.8
Current: 18.66
19.07
42.8
Revenue Growth (3Y)(%) 19.00
GRFS's Revenue Growth (3Y)(%) is ranked higher than
77% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GRFS: 19.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GRFS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 19  Med: 22.00 Max: 26.4
Current: 19
19
26.4
EBITDA Growth (3Y)(%) 33.90
GRFS's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. GRFS: 33.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GRFS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 28.7  Med: 33.80 Max: 33.9
Current: 33.9
28.7
33.9
EPS Growth (3Y)(%) 103.00
GRFS's EPS Growth (3Y)(%) is ranked higher than
97% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GRFS: 103.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GRFS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7  Med: 25.30 Max: 103
Current: 103
7
103
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

GRFS Guru Trades in Q1 2015

Mario Gabelli 27,868 sh (+16.27%)
John Paulson 17,801,740 sh (+0.05%)
Ron Baron 37,800 sh (unchged)
Jim Simons 77,002 sh (-17.29%)
» More
Q2 2015

GRFS Guru Trades in Q2 2015

Jim Simons 202,702 sh (+163.24%)
Mario Gabelli 30,200 sh (+8.37%)
John Paulson 17,821,040 sh (+0.11%)
Ron Baron 33,000 sh (-12.70%)
» More
Q3 2015

GRFS Guru Trades in Q3 2015

Steven Cohen 84,777 sh (New)
Ron Baron 35,000 sh (+6.06%)
John Paulson 17,729,140 sh (-0.52%)
Mario Gabelli 26,200 sh (-13.25%)
Jim Simons 8,302 sh (-95.90%)
» More
Q4 2015

GRFS Guru Trades in Q4 2015

Mario Gabelli 28,700 sh (+119.08%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.40
GRFS's P/E(ttm) is ranked higher than
61% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 32.30 vs. GRFS: 24.40 )
Ranked among companies with meaningful P/E(ttm) only.
GRFS' s P/E(ttm) Range Over the Past 10 Years
Min: 22.99  Med: 34.29 Max: 96.2
Current: 24.4
22.99
96.2
Forward P/E 12.95
GRFS's Forward P/E is ranked higher than
69% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 19.53 vs. GRFS: 12.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.30
GRFS's PE(NRI) is ranked higher than
61% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 32.00 vs. GRFS: 24.30 )
Ranked among companies with meaningful PE(NRI) only.
GRFS' s PE(NRI) Range Over the Past 10 Years
Min: 22.65  Med: 33.56 Max: 93.37
Current: 24.3
22.65
93.37
P/B 4.08
GRFS's P/B is ranked lower than
60% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. GRFS: 4.08 )
Ranked among companies with meaningful P/B only.
GRFS' s P/B Range Over the Past 10 Years
Min: 2.33  Med: 4.43 Max: 6.75
Current: 4.08
2.33
6.75
P/S 6.92
GRFS's P/S is ranked higher than
60% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. GRFS: 6.92 )
Ranked among companies with meaningful P/S only.
GRFS' s P/S Range Over the Past 10 Years
Min: 2.56  Med: 5.02 Max: 11.36
Current: 6.92
2.56
11.36
PFCF 72.96
GRFS's PFCF is ranked lower than
73% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.47 vs. GRFS: 72.96 )
Ranked among companies with meaningful PFCF only.
GRFS' s PFCF Range Over the Past 10 Years
Min: 15.32  Med: 28.92 Max: 115.5
Current: 72.96
15.32
115.5
POCF 17.25
GRFS's POCF is ranked higher than
66% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 30.00 vs. GRFS: 17.25 )
Ranked among companies with meaningful POCF only.
GRFS' s POCF Range Over the Past 10 Years
Min: 11.01  Med: 18.30 Max: 762
Current: 17.25
11.01
762
EV-to-EBIT 36.74
GRFS's EV-to-EBIT is ranked lower than
66% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 23.89 vs. GRFS: 36.74 )
Ranked among companies with meaningful EV-to-EBIT only.
GRFS' s EV-to-EBIT Range Over the Past 10 Years
Min: 15.8  Med: 24.75 Max: 87.7
Current: 36.74
15.8
87.7
EV-to-EBITDA 30.54
GRFS's EV-to-EBITDA is ranked lower than
66% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.19 vs. GRFS: 30.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
GRFS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.8  Med: 20.40 Max: 65.2
Current: 30.54
12.8
65.2
PEG 0.91
GRFS's PEG is ranked higher than
81% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. GRFS: 0.91 )
Ranked among companies with meaningful PEG only.
GRFS' s PEG Range Over the Past 10 Years
Min: 0.66  Med: 0.72 Max: 0.8
Current: 0.91
0.66
0.8
Current Ratio 2.91
GRFS's Current Ratio is ranked lower than
64% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. GRFS: 2.91 )
Ranked among companies with meaningful Current Ratio only.
GRFS' s Current Ratio Range Over the Past 10 Years
Min: 2.19  Med: 2.91 Max: 3.26
Current: 2.91
2.19
3.26
Quick Ratio 1.52
GRFS's Quick Ratio is ranked lower than
77% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GRFS: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
GRFS' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.46 Max: 1.88
Current: 1.52
1.15
1.88
Days Inventory 494.80
GRFS's Days Inventory is ranked lower than
96% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. GRFS: 494.80 )
Ranked among companies with meaningful Days Inventory only.
GRFS' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 286.75 Max: 811.74
Current: 494.8
235.92
811.74
Days Sales Outstanding 82.68
GRFS's Days Sales Outstanding is ranked lower than
61% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GRFS: 82.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
GRFS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.97  Med: 68.57 Max: 83.07
Current: 82.68
50.97
83.07
Days Payable 135.76
GRFS's Days Payable is ranked higher than
76% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. GRFS: 135.76 )
Ranked among companies with meaningful Days Payable only.
GRFS' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 158.22 Max: 257.68
Current: 135.76
64.56
257.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.34
GRFS's Dividend Yield is ranked higher than
79% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. GRFS: 2.34 )
Ranked among companies with meaningful Dividend Yield only.
GRFS' s Dividend Yield Range Over the Past 10 Years
Min: 0.38  Med: 0.68 Max: 1.54
Current: 2.34
0.38
1.54
Dividend Payout 0.32
GRFS's Dividend Payout is ranked higher than
51% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. GRFS: 0.32 )
Ranked among companies with meaningful Dividend Payout only.
GRFS' s Dividend Payout Range Over the Past 10 Years
Min: 0.53  Med: 0.70 Max: 0.77
Current: 0.32
0.53
0.77
Forward Dividend Yield 2.52
GRFS's Forward Dividend Yield is ranked higher than
80% of the 217 Companies
in the Global Biotechnology industry.

( Industry Median: 1.33 vs. GRFS: 2.52 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.34
GRFS's Yield on cost (5-Year) is ranked higher than
68% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. GRFS: 2.34 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GRFS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.38  Med: 0.68 Max: 1.72
Current: 2.34
0.38
1.72
3-Year Average Share Buyback Ratio -3.60
GRFS's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: -9.90 vs. GRFS: -3.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GRFS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.1  Med: -12.30 Max: -3.6
Current: -3.6
-15.1
-3.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.38
GRFS's Price/Median PS Value is ranked lower than
73% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. GRFS: 1.38 )
Ranked among companies with meaningful Price/Median PS Value only.
GRFS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 0.96 Max: 2.01
Current: 1.38
0.59
2.01
Price/Peter Lynch Fair Value 0.98
GRFS's Price/Peter Lynch Fair Value is ranked higher than
76% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. GRFS: 0.98 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
GRFS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.95  Med: 0.95 Max: 0.95
Current: 0.98
Earnings Yield (Greenblatt) (%) 2.70
GRFS's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. GRFS: 2.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GRFS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 4.00 Max: 6.3
Current: 2.7
1.1
6.3

More Statistics

Revenue(Mil) $3826
EPS $ 0.85
Beta1.16
Short Percentage of Float0.31%
52-Week Range $14.07 - 18.04
Shares Outstanding(Mil)687.55

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 4,101 4,279 4,397
EPS($) 1.23 1.34 1.60
EPS without NRI($) 1.23 1.34 1.60

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GIKLY.USA,
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma Feb 05 2016
Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the... Jan 26 2016
Grifols invests in the project led by AlbaJuna Therapeutics, a spin-off from IrsiCaixa, to fund the... Jan 26 2016
GRIFOLS SA Financials Jan 16 2016
How it All Plays Out - Analyst Reports on KapStone Paper and Packaging, Heartland Express, Grifols... Jan 13 2016
Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus and Diphtheria... Jan 08 2016
Grifols, S.A. downgraded by Morgan Stanley Jan 04 2016
8 Biotech Stocks That Should Be in Your Portfolio Right Now Dec 23 2015
Grifols makes public its succession plan: the envisaged generational handover reiterates the... Dec 14 2015
Grifols makes public its succession plan: the envisaged generational handover reiterates the... Dec 14 2015
Look for These Stock to Break Above Resistance Dec 07 2015
Is Grifols SA, Barcelona (GRFS) A Good Stock To Buy? Dec 02 2015
Here is What Hedge Funds Think About Textron Inc. (TXT) Dec 01 2015
Inauguration of the Grifols Chair for the Study of Cirrhosis Nov 30 2015
Should You Buy Goldcorp Inc. (USA) (GG)? Nov 27 2015
Is MGM Resorts International (MGM) A Good Stock To Buy? Nov 23 2015
Grifols (GRFS): Moving Average Crossover Alert Nov 06 2015
The intermediate results from the Grifols AMBAR study support its continuation Nov 06 2015
The intermediate results from the Grifols AMBAR study support its continuation Download (31.1 Kb) Nov 06 2015
Grifols’ net profit rises by 18.5% to exceed Euros 400 million, and revenue rises by 17.8% to... Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK